MORGAN STANLEY PLC/CALL/ABBVIE/175/0.1/20.09.24 Stock

Warrant

DE000MB09XA1

Market Closed - Börse Stuttgart 08:14:38 2024-06-27 am EDT
0.48 EUR -9.43% Intraday chart for MORGAN STANLEY PLC/CALL/ABBVIE/175/0.1/20.09.24
Current month+151.31%
1 month+203.80%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-27 0.48 -9.43%
24-06-26 0.53 +6.00%
24-06-25 0.5 -15.25%
24-06-24 0.59 +22.92%
24-06-21 0.48 -22.58%

Delayed Quote Börse Stuttgart

Last update June 27, 2024 at 08:14 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ABBVIE INC.
Issuer Morgan Stanley
WKN MB09XA
ISINDE000MB09XA1
Date issued 2022-11-08
Strike 175 $
Maturity 2024-09-20 (85 Days)
Parity 10 : 1
Emission price 1.37
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.94
Lowest since issue 0.119
Delta0.39x
Omega 15.17
Premium6.12x
Gearing38.98x
Moneyness 0.9657
Difference Strike 6.01 $
Difference Strike %+3.43%
Spread 0.01
Spread %2.44%
Theoretical value 0.4050
Implied Volatility 20.44 %
Total Loss Probability 64.48 %
Intrinsic value 0.000000
Present value 0.4050
Break even 179.34 €
Theta-0.03x
Vega0.03x
Rho0.01x

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
More about the company

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: AbbVie Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
169 USD
Average target price
183.2 USD
Spread / Average Target
+8.43%
Consensus